EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High anti-ADAMTS13 IgG Levels after Plasma Exchange Predict Delayed ADAMTS13 Normalization in Immune-mediated Thrombotic Thrombocytopenic Purpura

Marienn Réti, Andreea-Adela Icleanu iD, Andrea Várkonyi, Ágnes Király, Luca Bogsch, Zita Farkas, Péter Reményi, Zoltán Prohászka, György Sinkovits iD

Thrombosis and Haemostasis · 01.06.2026 · 126 (06) · 646-660

DOI: 10.1055/a-2685-8118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.06.2026. Verfasst von Marienn Réti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest - Institute of Hematology and Infectious Diseases, Budapest…. Hauptthemen laut MEDLINE: ADAMTS13 Protein, Plasma Exchange, Immunoglobulin G, Purpura, Thrombotic Thrombocytopenic. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Emberi Eroforrások Minisztériuma, HORIZON EUROPE 2021 Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In acute immune-mediated TTP (iTTP) caplacizumab therapy has proved to be effective in achieving an early clinical response. However, the discontinuation of caplacizumab therapy before ADAMTS13 activity has at least partially recovered can potentially lead to disease recurrence. Of note, normalization of ADAMTS13 activity was reported to be delayed in caplacizumab-treated patients. To investigate delayed ADAMTS13 normalization and its potential causes. We conducted a retrospective detailed longitudinal investigation of ADAMTS13 activity and anti-ADAMTS13 IgG levels in a single-center cohort of caplacizumab-treated iTTP patients (n = 10). Results were compared to iTTP patients treated according to the standard of care in the same center, without caplacizumab (historical controls, n = 28). We observed that ADAMTS13 activity was lower in caplacizumab-treated patients than in historical controls 1 week after therapeutic plasma exchange (TPE) was discontinued upon first clinical response (post-TPE). The difference later gradually decreased and we observed no delay in attaining ADAMTS13 activity thresholds of 20% (partial ADAMTS13 remission, reached in median 26 vs. 25 days after the first TPE session) or higher. However, almost half of the caplacizumab-treated patients needed more than 30 days to achieve partial ADAMTS13 remission. Importantly, we found that the post-TPE anti-ADAMTS13 IgG level correlates with the time until partial ADAMTS13 remission both in caplacizumab-treated and historical control patients, and is a significant predictor of delayed ADAMTS13 normalization. The latter finding has important clinical implications, as it suggests that measuring post-TPE anti-ADAMTS13 IgG levels may help identify patients who need additional immunosuppressive treatment to avoid delayed ADAMTS13 normalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 ProteinPlasma ExchangeImmunoglobulin GPurpura, Thrombotic ThrombocytopenicAutoantibodiesHumansFemaleRetrospective StudiesMaleMiddle AgedAdultTreatment OutcomeTime FactorsLongitudinal StudiesAgedRecurrencePredictive Value of TestsImmunosuppressive AgentsSingle-Domain Antibodies

Substanzen

ADAMTS13 ProteinADAMTS13 protein, humanImmunoglobulin GcaplacizumabAutoantibodiesImmunosuppressive AgentsSingle-Domain Antibodies

Autor:innen und Institutionen

  • Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest - Institute of Hematology and Infectious Diseases, Budapest, Hungary.
  • Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
  • Research Group for Immunology and Hematology, Semmelweis University - Hungarian Research Network (Office for Supported Research Groups), Budapest, Hungary.

ORCID-Profile: Andreea-Adela Icleanu, György Sinkovits

Förderung

  • Emberi Eroforrások Minisztériuma
  • HORIZON EUROPE 2021 Research and Innovation

Zitieren

APA

Réti, M., Icleanu, A. A., Várkonyi, A., Király, Á., Bogsch, L., Farkas, Z., Reményi, P., Prohászka, Z., & Sinkovits, G. (2026). High anti-ADAMTS13 IgG Levels after Plasma Exchange Predict Delayed ADAMTS13 Normalization in Immune-mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 126(06), 646-660. https://doi.org/10.1055/a-2685-8118

Vancouver

Réti M, Icleanu AA, Várkonyi A, Király Á, Bogsch L, Farkas Z, et al. High anti-ADAMTS13 IgG Levels after Plasma Exchange Predict Delayed ADAMTS13 Normalization in Immune-mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis. 2026;126(06):646-660. doi:10.1055/a-2685-8118

BibTeX
@article{Rti2026,
  author = {Réti, Marienn and Icleanu, Andreea-Adela and Várkonyi, Andrea and Király, Ágnes and Bogsch, Luca and Farkas, Zita and Reményi, Péter and Prohászka, Zoltán and Sinkovits, György},
  title = {High anti-ADAMTS13 IgG Levels after Plasma Exchange Predict Delayed ADAMTS13 Normalization in Immune-mediated Thrombotic Thrombocytopenic Purpura},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {06},
  pages = {646--660},
  doi = {10.1055/a-2685-8118}
}
Kostenlos starten →